<DOC>
	<DOC>NCT00586495</DOC>
	<brief_summary>Extension to study 11515 (NCT00661375) which was a multicenter study of sorafenib in patients with renal cell carcinoma (RCC).</brief_summary>
	<brief_title>Long-term Extension From RCC Phase II (11515)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients are classified into two groups as below at transition date from Study 11515 to this study. Population I: Patients who are willing to continue the study drug, for whom the investigator consider continuation of the study drug is appropriate, and who do not meet the criteria of removal from the study in Study 11515 at the end of Study 11515. Population II: Patients who have been monitored only for survival status at the end of Study 11515. Population 1 1. Patients who are willing to continue the study drug, 2. Patients for whom the investigator consider continuation of the study drug is appropriate 3. Patients who do not meet the criteria of removal from the study in Study 11515 at the end of Study 11515. 4. Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice. Population 2 1. Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice. 1. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results 2. Any condition that could jeopardize the safety of the patient or that affect his/her compliance in the study 3. Pregnant or breastfeeding patients. Both men and women enrolled in this trial must use adequate birth control.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Metastatic RCC</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Unresectable RCC</keyword>
</DOC>